Sugi Predict

Sugi Predict / Compounds / SCHEMBL313807

SCHEMBL313807

SCHEMBL313807

Nc1ncc2cc[nH]c2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ULK1 O75385 1/20 0.43
▸ AXL P30530 2/20 0.42
▸ NUDT1 P36639 1/20 0.42
▸ DYRK1A Q13627 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.39
▸ CDK8 P49336 2/20 0.39
▸ PIK3CA P42336 2/20 0.39
▸ MAPK1 P28482 2/20 0.38
▸ PIK3CD O00329 1/20 0.38
▸ PIK3CB P42338 1/20 0.38
▸ PIK3CG P48736 1/20 0.38
▸ RIPK1 Q13546 2/20 0.37
▸ FGFR1 P11362 1/20 0.37
▸ ADORA2A P29274 1/20 0.37
▸ ADORA1 P30542 1/20 0.37
▸ HRH4 Q9H3N8 1/20 0.37
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ MAP3K11 Q16584 1/20 0.36
▸ IKBKB O14920 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29755564 1.00 ULK1 (0.43) ULK1AXLNUDT1DYRK1AALDH1A1
SCHEMBL14555749 0.75 AXL (0.39) AXLNUDT1DYRK1AALDH1A1CDK8
SCHEMBL28000102 0.74 AXL (0.42) AXLNUDT1DYRK1ACDK8PIK3CA
SCHEMBL28330507 0.74 AXL (0.42) AXLNUDT1DYRK1ACDK8PIK3CA
SCHEMBL4217784 0.74 AXL (0.42) AXLNUDT1CDK8PIK3CAMAPK1
SCHEMBL15917037 0.74 MAPK1 (0.47) AXLNUDT1DYRK1ACDK8PIK3CA
SCHEMBL167083 0.74 AXL (0.42) AXLNUDT1CDK8PIK3CAMAPK1
SCHEMBL1442938 0.74 AXL (0.42) AXLNUDT1DYRK1ACDK8PIK3CA
SCHEMBL29080063 0.74 CDK8 (0.42) AXLNUDT1DYRK1ACDK8PIK3CA
Hydrochloric Acid SCHEMBL29247907 0.72 AXL (0.41) AXLNUDT1CDK8PIK3CAMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 393 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4341264-B1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS DRUGS FOR NEGLECTED DISEASES INITIATIVE (CH) 2025-04-02 — — EP claimed
EP-4415818-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BioSplice Therapeutics, Inc. (US) 2024-08-21 — — EP claimed
EP-4341264-A1 PYRROLOPIRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LEISHMANIASIS Drugs for Neglected Diseases Initiative (CH) 2024-03-27 — — EP claimed
CN-117263940-A FGFR inhibitor, preparation method thereof, pharmaceutical composition and application 中国药科大学 2023-12-22 — — CN claimed
CN-111936144-B JAK inhibitors 廖细斌 2023-12-22 — — CN claimed
CN-111819176-B 4-azaindole compounds 百时美施贵宝公司 2023-12-15 — — CN claimed
EP-3722298-B1 PYRROLO(PYRAZOLO)PYRIMIDINE DERIVATIVE AS LRRK2 INHIBITOR OSCOTEC INC (KR) 2023-08-02 — — EP claimed
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF VICKERS VENTURE FUND VI PTE. LTD. (SG) 2023-06-01 — — US claimed
WO-2023064361-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AS DYRK1A INHIBITORS BIOSPLICE THERAPEUTICS, INC. (US) 2023-04-20 — — WO claimed
CN-115684424-A LC-MS/MS-based method for detecting 4-chloro-7H-pyrrolo [2,3-d ] pyrimidine in soil and water 贵州健安德科技有限公司 2023-02-03 — — CN claimed
CN-115023221-A Stable immediate release tablet and capsule formulations of 1- ((2S,5R) -5- ((7H-pyrrolo [2,3-D ] pyrimidin-4-yl) amino) -2-methylpiperidin-1-yl) prop-2-en-1-one 辉瑞英国研发有限公司 2022-09-06 — — CN claimed
CN-114466681-A 7H-pyrrolo [2,3-D ] pyrimidine JAK inhibitors 礼蓝美国公司 2022-05-10 — — CN claimed
WO-2020235902-A1 HETEROCYCLE-FUSED PYRIMIDINE DERIVATIVE AND USE THEREOF 주식회사 보로노이 (KR) 2020-11-26 — — WO claimed
EP-2391619-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS Millennium Pharmaceuticals, Inc. (US) 2011-12-07 — — EP claimed
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2011-09-08 — — US claimed
EP-2294071-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. Organon (NL) 2011-03-16 — — EP claimed
US-20110003806-A1 Heteroaryls and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2011-01-06 — — US claimed
WO-2010090716-A1 HETEROARYLS AND THEIR USE AS PI3K INHIBITORS MILLENNIUM PHARMACEUTICALS, INC. (US) 2010-08-12 — — WO claimed
WO-2009124965-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS N.V. ORGANON (NL) 2009-10-15 — — WO claimed
WO-2009049028-A1 PYRROLOPYRIMIDINE COMPOUNDS AND THEIR USE AS JANUS KINASE MODULATORS TARGEGEN INC. (US) 2009-04-16 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110218189-A1 PYRROLO[2,3-d]PYRIMIDIN-2-YL-AMINE DERIVATIVES AS PKC-THETA INHIBITORS PRKCZ, PRKCQ, PRKCD ULK1 1297/4885AXL 1724/4885NUDT1 2159/4885
US-20230167133-A1 7H-PYRROLO[2,3-D]PYRIMIDINES AND PREPARATION AND USES THEREOF DYRK1A, DYRK1B, DYRK2 ULK1 266/4885AXL 2487/4885NUDT1 483/4885
US-20110003806-A1 Heteroaryls and uses thereof RICTOR, MTOR, AKT1S1 ULK1 132/4885AXL 1745/4885NUDT1 2464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.